I think a lot of folks had not expected them to be back this quickly.

If they do negotiate a lower price, they may open themselves up to litigation by essentially conceding that there has been a problem under management's watch.

You can't just sit back on your laurels. You have to constantly innovate.

If the deals went to shareholders today, we believe Boston Scientific would prevail.

I don't see material upside or downside (for Boston Scientific shares) for the next 12 months.

[MacMillan] has big shoes to fill and he's inheriting a legacy of 20% earnings growth.